<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38141960</PMID><DateCompleted><Year>2024</Year><Month>02</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-3511</ISSN><JournalIssue CitedMedium="Internet"><Volume>140</Volume><PubDate><Year>2024</Year><Month>Mar</Month></PubDate></JournalIssue><Title>International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases</Title><ISOAbbreviation>Int J Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Patients with Long COVID continue to experience significant symptoms at 12 months and factors associated with improvement: A prospective cohort study in France (PERSICOR).</ArticleTitle><Pagination><StartPage>9</StartPage><EndPage>16</EndPage><MedlinePgn>9-16</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijid.2023.11.038</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1201-9712(23)00798-1</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">This study examines long COVID symptoms course over 12 months, their impact on daily life, and associated factors for symptom relief.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A prospective cohort study included 231 participants with long COVID at 12-month follow-up. Data on characteristics, symptom course, and remission were collected using a questionnaire and a remission scale. Poisson regression models were used to estimate the prevalence rate ratio (PRR) and 95% confidence intervals (CIs) for factors associated with symptom improvement.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 231 participants, 63.2% developed SARS-CoV-2 antibodies before COVID-19 vaccination. At 12 months, only 8.7% (95% CI: 5.4-13.1%) reported complete remission, while 28.6% noted significant improvement. Most symptoms remained prevalent: asthenia (83.1%), neurocognitive/neurological (93.9%), cardiothoracic (77.9%), Musculoskeletal (78.8%). During long COVID, 62.2% stopped working, and only 32.5% resumed full-time professional activities. Presence of SARS-CoV-2 antibodies before vaccination increased the probability of improvement (aPRR: 1.60, P = 0.028), while ageusia at initial long COVID phase decreased the probability (aPRR: 0.38, P = 0.007).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Long-COVID symptoms persisted in the majority of participants after 12 months, with significant impacts on daily life and work. SARS-CoV-2 antibodies were associated with better prognosis, while persistent ageusia indicated a lower probability of improvement. These findings highlight the need for ongoing support and care for individuals with long COVID.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Salmon</LastName><ForeName>Dominique</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institut Fournier, Department of International Relations, Assistance Publique H&#xf4;pitaux de Paris (APHP), University of Paris Cit&#xe9; Paris, Paris, France. Electronic address: dominique.salmon@aphp.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Slama</LastName><ForeName>Dorsaf</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Villeneuve Saint Georges Hospital, Villeneuve Saint Georges, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Linard</LastName><ForeName>Fran&#xe7;oise</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Psychiatry, Department of Infectious Diseases, Hotel Dieu Hospital, Assistance Publique H&#xf4;pitaux de Paris (APHP), Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dumesges</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>General Practitioner, Department of Infectious Diseases, Hotel Dieu Hospital, Assistance Publique H&#xf4;pitaux de Paris (APHP), Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le Baut</LastName><ForeName>Val&#xe9;rie</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Clinical Research Technician, Department of Infectious Diseases, Hotel Dieu Hospital, Assistance Publique H&#xf4;pitaux de Paris (APHP), Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hakim</LastName><ForeName>Florence</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Clinical Research Technician, Department of Infectious Diseases, Hotel Dieu Hospital, Assistance Publique H&#xf4;pitaux de Paris (APHP), Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oustric</LastName><ForeName>Pauline</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>ApresJ20 Association, Luc&#xe9;, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seyrat</LastName><ForeName>Emilie</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Espoirs Association, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thoreux</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Sports Medicine, Hotel Dieu Hospital, Assistance Publique H&#xf4;pitaux de Paris (APHP), University of Paris Sorbonne, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marshall</LastName><ForeName>Esaie</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Sorbonne University, INSERM, Pierre Louis Institute of Epidemiology and Public Health, Paris, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>12</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>Int J Infect Dis</MedlineTA><NlmUniqueID>9610933</NlmUniqueID><ISSNLinking>1201-9712</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000370" MajorTopicYN="Y">Ageusia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antibodies cognitive impairment</Keyword><Keyword MajorTopicYN="N">Follow-up</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Post-acute sequelae of SARS-CoV-2 (PACS)</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Social consequences</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors have no competing interests to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>11</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>11</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>12</Month><Day>24</Day><Hour>9</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>12</Month><Day>23</Day><Hour>19</Hour><Minute>29</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38141960</ArticleId><ArticleId IdType="doi">10.1016/j.ijid.2023.11.038</ArticleId><ArticleId IdType="pii">S1201-9712(23)00798-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>